

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IB2010/003106

International filing date: 18 November 2010 (18.11.2010)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 61/382,709  
Filing date: 14 September 2010 (14.09.2010)

Date of receipt at the International Bureau: 26 November 2010 (26.11.2010)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a),(b) or (b-bis)





THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*November 25, 2010*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 61/382,709**

**FILING DATE: *September 14, 2010***

**RELATED PCT APPLICATION NUMBER: *PCT/US10/57192***

**THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US61/382,709***



Certified by

*David J. Kappas*

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET – Page 1 of 2**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. N/A - efiled on September 14, 2010

INVENTOR(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Fabio	Trento	Como, Italy
Sergio	Cantoreggi	Vezia, Switzerland
Georgia	Rossi	Como, Italy

*Additional inventors are being named on the \_\_\_\_\_ separately numbered sheets attached hereto.*

**TITLE OF THE INVENTION (500 characters max):**

METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING

*Direct all correspondence to:* **CORRESPONDENCE ADDRESS**

The address corresponding to Customer Number: 53449

**OR**

Firm or Individual Name

Address

City	State	Zip
Country	Telephone	Email

**ENCLOSED APPLICATION PARTS (check all that apply)**

Application Data Sheet. See 37 CFR 1.76

CD(s), Number of CDs \_\_\_\_\_

Drawing(s) *Number of Sheets* 5

Other (specify) \_\_\_\_\_

Specification (e.g. description of the invention) *Number of Pages* 25

Fees Due: Filing Fee of \$220 (\$110 for small entity). If the specification and drawings exceed 100 sheets of paper, an application size fee is also due, which is \$270 (\$135 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

**METHOD OF PAYMENT OF THE FILING FEE AND APPLICATION SIZE FEE FOR THIS PROVISIONAL APPLICATION FOR PATENT**

Applicant claims small entity status. See 37 CFR 1.27.

A check or money order made payable to the *Director of the United States Patent and Trademark Office* is enclosed to cover the filing fee and application size fee (if applicable).

Payment by credit card. ~~Form PTO 2008 5 is attached.~~

The Director is hereby authorized to charge the filing fee and application size fee (if applicable) or credit any overpayment to Deposit Account Number: \_\_\_\_\_.

\$110.00  
**TOTAL FEE AMOUNT (\$)**

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

PROVISIONAL APPLICATION COVER SHEET  
Page 2 of 2

PTO/SB/16 (12-08)  
Approved for use through 06/30/2010. OMB 0651-0032  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes, the name of the U.S. Government agency and the Government contract number are: \_\_\_\_\_

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

SIGNATURE /Clark G. Sullivan/ Date September 14, 2010

TYPED or PRINTED NAME Clark G. Sullivan REGISTRATION NO. 36,942  
(if appropriate)

TELEPHONE 404.873.8512 Docket Number: 23278.20.8401

## Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

CLAIMS

- 1) A method of treating nausea and vomiting for five consecutive days in a patient in need thereof, consisting essentially of:
  - a) administering to said patient on day one netupinant or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases, and which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration;
  - b) administering to said patient on day one a therapeutically effective amount of a 5-HT<sub>3</sub> antagonist which is effective to treat nausea and vomiting during the acute and delayed phases;
  - c) administering to said patient on day one a first dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupinant, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone; and
  - d) when the patient is undergoing highly emetogenic chemotherapy, administering to said patient, on days two, three and four, a second dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupinant, wherein said second dose comprises from 40 to 60% of a minimum effective dose when administered alone.
- 2) A method of treating nausea and vomiting for a period of five consecutive days in a patient in need thereof, comprising administering to said patient netupinant or a pharmaceutically acceptable salt thereof, in a therapeutically effective amount which is effective to treat nausea and vomiting during the acute and delayed phases, and which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration.
- 3) The method of claim 1 or 2, wherein said netupinant occupies at least 80% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration.

- 4) The method of claim 1 or 2, wherein only one dose of netupitant or a pharmaceutically acceptable salt thereof is administered during said five days.
- 5) The method of claim 1 or 2, wherein only one dose of netupitant or a pharmaceutically acceptable salt thereof is administered during said five days, and said one dose is administered orally.
- 6) The method of claim 1 or 2, wherein said therapeutically effective amount of netupitant comprises from about 200 to about 400 mg. of netupitant or a pharmaceutically acceptable salt thereof.
- 7) The method of claim 1 or 2, wherein said therapeutically effective amount of netupitant comprises about 300 mg. of netupitant as a free base.
- 8) The method of claim 2, further comprising:
  - a) administering to said patient on day one a first dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone; and
  - b) if said patient is undergoing highly emetogenic chemotherapy, administering to said patient, on days two, three and four, a second dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said second dose comprises from 40 to 60% of a minimum effective dose when administered alone.
- 9) The method of claim 1 or 8, comprising orally administering:
  - a) about 300 mg. of netupitant as a free base on day one;
  - b) about 12 mg. of dexamethasone on day one; and
  - c) if said patient is undergoing highly emetogenic chemotherapy, about 8 mg. of dexamethasone on days two, three and four.
- 10) The method of claim 2, further comprising administering a therapeutically effective amount of a 5-HT<sub>3</sub> antagonist.

- 11) The method of claim 10, wherein only one dose of said 5-HT<sub>3</sub> antagonist is administered during said five days, and said dose of 5-HT<sub>3</sub> antagonist is effective to treat said nausea when evaluated during days two through five after said administration.
- 12) The method of claim 1, 9 or 10, wherein:
  - a) only one dose of netupitant is administered during said five days on day one, comprising about 300 mg. of netupitant as the free base; and
  - b) only one dose of a 5-HT<sub>3</sub> antagonist is administered during said five days on day one, comprising about 0.50 mg. of palonosetron hydrochloride, based on the weight of the free base.
- 13) The method of claim 1 or 2, comprising administering highly emetogenic chemotherapy within about one hour of said administration of said netupitant or pharmaceutically acceptable salt thereof.
- 14) The method of claim 1 or 2, comprising treating nausea and vomiting in response to highly emetogenic chemotherapy during the acute phase.
- 15) The method of claim 1 or 2, comprising treating nausea and vomiting in response to highly emetogenic chemotherapy during the delayed phase.
- 16) The method of claim 1 or 2, comprising treating nausea and vomiting in response to moderately emetogenic chemotherapy during the acute phase.
- 17) The method of claim 1 or 2, comprising treating nausea and vomiting in response to moderately emetogenic chemotherapy during the delayed phase.
- 18) A method of treating nausea and vomiting in a human subject in need thereof, during the acute and/or delayed phases of CINV in response to moderately or highly emetogenic chemotherapy, comprising administering a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of palonosetron, or a pharmaceutically acceptable salt thereof, before said chemotherapy.
- 19) The method of claim 18, comprising orally administering from about 200 to about 400 mg. of netupitant or a pharmaceutically acceptable salt thereof, and from about 0.25 to about 0.75 mg. of palonosetron or a pharmaceutically acceptable salt thereof.
- 20) The method of claim 18, comprising orally administering about 300 mg. of netupitant as the free base, and about 0.50 mg. of palonosetron as palonosetron hydrochloride, based on the weight of the free base.

- 21) The method of claim 18, 19 or 20, further comprising, if said patient is undergoing highly emetogenic chemotherapy, administering a sub-therapeutic dose of dexamethasone on days one, two, three and four.
- 22) The method of claim 18, 19 or 20, further comprising, if said patient is undergoing highly emetogenic chemotherapy, orally administering 12 mg. of dexamethasone on day one, and 8 mg. of dexamethasone on days two, three and four.

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	8416801
<b>Application Number:</b>	61382709
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1712
<b>Title of Invention:</b>	Methods for Treating Centrally Mediated Nausea and Vomiting
<b>First Named Inventor/Applicant Name:</b>	Fabio Trento
<b>Customer Number:</b>	53449
<b>Filer:</b>	Clark G. Sullivan/Pamela Mackey
<b>Filer Authorized By:</b>	Clark G. Sullivan
<b>Attorney Docket Number:</b>	23278.20.8401
<b>Receipt Date:</b>	14-SEP-2010
<b>Filing Date:</b>	
<b>Time Stamp:</b>	16:39:04
<b>Application Type:</b>	Provisional

### Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$110
RAM confirmation Number	3161
Deposit Account	
Authorized User	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
-----------------	----------------------	-----------	-------------------------------------	------------------	------------------

1	Provisional Cover Sheet (SB16)	23278_20_8401_2010_09_14_AMD_AFD_Provisional_Cover_Sheet.pdf	963456 6aa76f95608e33f21d507c08f1a7fd40152161a	no	3
<b>Warnings:</b>					
This is not a USPTO supplied Provisional Cover Sheet SB16 form.					
<b>Information:</b>					
2	Specification	23278_20_8401_2010_09_14_AMD_AFD_Netupitant_emesis_provisional_application.pdf	369783 7283d83929cfdfa83bed28b487124b2139cc574	no	31
<b>Warnings:</b>					
<b>Information:</b>					
3	Fee Worksheet (PTO-875)	fee-info.pdf	29305 0b8472846a5648414935b3bb5314d10aec1c427	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				1362544	
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  <b>If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</b></p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  <b>If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</b></p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  <b>If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</b></p>					

METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING

ABSTRACT

Provided are synergistically effective combinations of netupitant and palonosetron for central nausea control.

1/5




Figure 1

2/5




Figure 2

3/5




Figure 3

4/5




Figure 4: Dexamethasone Mean Plasma Concentrations Versus Time, With and Without Co-administration of Netupitant.

5/5




Figure 5: Average Neurokinin 1 Receptor Occupancy (NK<sub>1</sub>-RO), Obtained at 6, 24, 48, 72 and 96 Hours after a Single Oral Dose of 100, 300 and 450 mg. netupitant (N=2 for each dose) in Striatum and Occipital Cortex, PET Study

**PROVISIONAL APPLICATION FOR  
UNITED STATES PATENT**

for

**METHODS FOR TREATING CENTRALLY MEDIATED  
NAUSEA AND VOMITING**

by:

FABIO TRENTO, a citizen of Italy residing at Via Alla Valle 20B  
I-22020 Paré (Como - Italy); SERGIO CANTOREGGI, a citizen of Switzerland  
residing at Via ai Ronchi, 37 CH-6943 Vezia Switzerland; and GEORGIA ROSSI,  
a citizen of Italy residing at Via della Libertà, 1A I-22012 Cernobbio (Como -  
Italy).

## METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITING

### FIELD OF THE INVENTION

The present invention relates to the use of centrally acting NK<sub>1</sub> antagonists to treat nausea and vomiting, particular nausea and vomiting induced by highly emetogenic chemotherapy, and to the treatment of such nausea and vomiting over multiple consecutive days.


### BACKGROUND OF THE INVENTION

With the development of the 5-HT<sub>3</sub> antagonist in the early 1990s, there emerged new strategies in the medical community to better control nausea and vomiting caused by various medical procedures, including chemotherapy (CINV), surgery (PONV), and radiation therapy (RINV). When added to steroids such as dexamethasone, several 5-HT<sub>3</sub> antagonists have been demonstrated to significantly improve the standard of life for patients undergoing emetogenic medical procedures. Examples of 5-HT<sub>3</sub> antagonists include ondansetron, marketed by GlaxoSmithKline, and palonosetron, developed by Helsinn Healthcare.

NK<sub>1</sub> antagonists have also recently emerged as a tool for combating nausea and vomiting from emetogenic medical procedures. Most recently, aprepitant was approved by the Food and Drug Administration (“FDA”) for use in combination with other anti-emetic agents for the prevention of nausea and vomiting from moderately and highly emetogenic chemotherapy. However, it quickly became apparent that aprepitant’s effect was limited principally to vomiting – not nausea – and that aprepitant did not provide as much benefit during the acute phase of CINV. When tested against nausea in humans, aprepitant was unable to induce a significant reduction in the incidence or severity of nausea following moderately or highly emetogenic chemotherapy when compared to a 5-HT<sub>3</sub> antagonist alone. See FDA Approved Labeling for Emend<sup>®</sup>. Thus, while aprepitant is approved by FDA for the prevention of nausea and vomiting in humans, this indication is somewhat misleading because aprepitant did not reduce nausea in the clinical trials performed for aprepitant more than nausea controlled by the other components of the anti-emetic regimen.

Casopitant is another NK<sub>1</sub> antagonist that has been tested against nausea and vomiting in humans, and while it has demonstrated some effect against nausea, its effects have been inconsistent. As reported by Ruhlmann *et al.* in THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2009:5 375-384, casopitant had no statistically significant effect against nausea when administered in response to moderately emetogenic chemotherapy, and even induced nausea as a side effect.

Netupitant is another selective NK<sub>1</sub> receptor antagonist under development by Helsinn Healthcare, having the formula 2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-yl]propanamide, or Benzeneacetamide, N, $\alpha$ , $\alpha$ -trimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)-, and the below chemical structure:



Methods of synthesizing and formulating netupitant and its prodrugs are described in U.S. Patent Nos. 6,297,375, 6,719,996 and 6,593,472 to Hoffmann La Roche.

The background of U.S. Patent No. 6,297,375 suggests that NK<sub>1</sub> antagonists are useful for treating a variety of conditions in which substance P (the natural ligand for the NK<sub>1</sub> receptor) is active. These conditions include depression, pain (especially pain resulting from inflammatory conditions such as migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease), central nervous system (CNS) disorders such as Parkinson's disease and Alzheimer's disease, headache, anxiety, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases. The background even mentions motion sickness and vomiting, but fails to call out nausea specifically.

Accordingly, there is a need in the art for more effective treatments of nausea and vomiting, particularly nausea and vomiting emanating from chemotherapy, radiotherapy and

surgery. In addition, given the prolonged incidence of nausea and vomiting induced by these emetic events, there is a need for treating such nausea and vomiting for a prolonged period of time.

### OBJECTS OF THE INVENTION

Accordingly, it is an object of the invention to provide new methods for treating or preventing nausea and vomiting using an NK<sub>1</sub> antagonist, particularly netupitant.

It is another object of the invention to provide methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

Still another object of the invention is to augment existing treatments for CINV, RINV or PONV by steroids and 5-HT<sub>3</sub> antagonists, and thereby provide additional protection against both nausea and vomiting, especially during the acute and delayed phases.

Another object of the invention is to provide a single combined dose of netupitant and a 5-HT<sub>3</sub> antagonist and to the use of that single dose without further dosing, for the treatment of nausea and vomiting during the acute and delayed phases of CINV, RINV or PONV.

It is another object to provide novel methods to treat nausea, vomiting, and other undesirable effects from moderately emetogenic and highly emetogenic chemotherapy (“MEC and HEC”), especially HEC, during the acute and delayed phases following such treatments.

### SUMMARY OF THE INVENTION

After extensive testing into the clinical effects of netupitant, it has unexpectedly been discovered that netupitant is active against nausea, and that a single dose of netupitant is able to treat nausea and vomiting in response to highly and moderately emetogenic chemotherapy for five consecutive days. It has also been discovered, quite unexpectedly, that netupitant exhibits unique binding habits to NK<sub>1</sub> receptors in the brain. In particular, it has been discovered that netupitant binds to NK<sub>1</sub> receptors in the striatum in a long-lasting manner, and that less than 20 or 30% of netupitant is released from striatum NK<sub>1</sub> receptors even ninety-six hours after administration. This is in stark contrast to aprepitant, in which receptor binding drops swiftly over time, and must be dosed repeatedly if emesis control is desired throughout the delayed phase.

These discoveries have led to the development of a unique dosing regimen to treat nausea during the first day after an emesis-inducing event, in addition to the second, third, fourth and fifth days after such induction. Therefore, in one embodiment the invention provides a method of treating nausea and vomiting for a period of five consecutive days in a patient in need thereof, comprising administering to said patient netupitant or a pharmaceutically acceptable salt thereof in an amount which is therapeutically effective against nausea and vomiting during the acute and delayed phases, and which is effective to enter the systemic circulation, cross the blood brain barrier and occupy at least 70% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration.

In another embodiment, the netupitant is combined with other anti-emetic agents, including a 5-HT<sub>3</sub> antagonist such as palonosetron and a corticosteroid such as dexamethasone, in a manner that results in even greater efficacy against nausea. When administered as a combination therapy in this manner, it has been discovered that netupitant potentiates the effect of dexamethasone, such that the dexamethasone is effective even when administered at sub-therapeutic doses (i.e. doses at which the dexamethasone would be ineffective if administered by itself). Therefore, in another embodiment the invention provides a combination therapy for treating nausea and vomiting for five consecutive days in a patient in need thereof, consisting essentially of:

- Day 1 netupitant -- administering to said patient on day one netupitant or a pharmaceutically acceptable salt thereof, in an amount which is therapeutically effective against nausea and vomiting during the acute and delayed phases, and which is effective to enter the systemic circulation, cross the blood brain barrier and occupy at least 70% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration;
- Day 1 palonosetron -- administering to said patient on day one a therapeutically effective amount of a 5-HT<sub>3</sub> antagonist (preferably palonosetron) effective to treat said nausea and vomiting during the acute and delayed phases;
- Day 1 dexamethasone -- administering to said patient on day one a first dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant and palonosetron, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone; and
- Days 2-5 dexamethasone – when the patient is undergoing highly emetogenic chemotherapy, administering to said patient, on days two, three and four, a second dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with

said netupitant, wherein said second dose comprises from 40 to 60% of a minimum effective dose when administered alone on days two, three and four.

Additional embodiments and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The embodiments and advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.

FIG. 1 depicts a capsule containing one soft-gel capsule of palonosetron and three tablets of netupitant.

FIG. 2 is a two dimensional graph plotting the pharmacokinetic profile of netupitant in humans following oral administration of netupitant alone and netupitant together with palonosetron.

FIG. 3 is a two dimensional graph plotting the pharmacokinetic profile of palonosetron in humans following oral administration of palonosetron alone and palonosetron together with netupitant.

FIG. 4 is a two dimensional graph plotting mean plasma concentrations of dexamethasone over time following administration with and without netupitant.

FIG. 5 contains two bar graphs that depict the average NK<sub>1</sub> receptor occupancy at 6, 24, 48, 72 and 96 hours after a single oral dose of 100, 300 and 450 mg. netupitant (N=2 for each dose) in striatum and occipital cortex, as measured using positron emission topography.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention may be understood more readily by reference to the following definitions and detailed description of preferred embodiments of the invention and the non-limiting Examples included therein.

### Definitions and Use of Terms

When the singular forms “a,” “an” and “the” or like terms are used herein, they will be understood to include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a pharmaceutical carrier” includes mixtures of two or more such carriers, and the like. The word “or” or like terms as used herein means any one member of a particular list and also includes any combination of members of that list.

When used herein the term “about” or “ca.” will compensate for variability allowed for in the pharmaceutical industry and inherent in pharmaceutical products, such as differences in product strength and bioavailability due to manufacturing variations and time-induced product degradation. The term allows for any variation which in the practice of pharmaceuticals would allow the product being evaluated to be considered pharmaceutically equivalent or bioequivalent, or both if the context requires, to the recited strength of a claimed product.

Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited to,” and is not intended to exclude, for example, other additives, components, integers or steps.

As used herein, the term “pharmaceutically acceptable salt” refers to a salt of a compound to be administered prepared from pharmaceutically acceptable non-toxic acids. Examples of suitable inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, and phosphoric. Suitable organic acids may be selected from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, camphorsulfonic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, paratoluenesulfonic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic (besylate), stearic, sulfanilic, alginic, galacturonic, and the like.

When dose amounts are expressed herein in reference to a salt of an active ingredient, it will be understood that the amount expressed is based on the corresponding amount of the free base of the ingredient. Thus, for a salt of netupitant with a molecular weight of 600, if this document referred to the administration of 100 mg. of the salt, it would be understood that 125.36 mg. of the salt is administered, since the molecular weight of the salt would be 125.36% of the molecular weight of the netupitant base.


As used herein, “therapeutically effective amount” refers to an amount sufficient to elicit the desired biological response. The therapeutically effective amount or dose will depend on the age, sex and weight of the patient, and the current medical condition of the patient. The skilled artisan will be able to determine appropriate dosages depending on these and other factors in addition to the present disclosure.

The minimum effective dose of dexamethasone, when used to treat CINV induced by highly emetogenic chemotherapy, has been demonstrated to be 20 mg. administered orally or by injection on day one, and sixteen mg. administered orally or by injection on days two, three and four. Jordan *et al.*, THE ONCOLOGIST, Vol. 12, No. 9, 1143-1150, September 2007. When used to treat CINV induced by moderately emetogenic chemotherapy, the minimum effective dose of dexamethasone is 20 mg. administered orally or by injection on day one, and zero mg. on days two, three and four.

The terms “treating” and “treatment,” when used herein, refer to the medical management of a patient with the intent to cure, ameliorate, stabilize, or prevent a disease, pathological condition, or disorder. This term includes active treatment, that is, treatment directed specifically toward the improvement of a disease, pathological condition, or disorder, and also includes causal treatment, that is, treatment directed toward removal of the cause of the associated disease, pathological condition, or disorder. In addition, this term includes palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder.

As used herein, the term “significantly” refers to a level of statistical significance. The level of statistical significant can be, for example, of at least  $p < 0.05$ , of at least  $p < 0.01$ , of at least  $p < 0.005$ , or of at least  $p < 0.001$ . Unless otherwise specified, the level of statistical significance is  $p < 0.05$ . When a measurable result or effect is expressed or identified herein, it will be understood that the result or effect is evaluated based upon its statistical significance relative to a baseline. In like manner, when a treatment is described herein, it will be understood that the treatment shows efficacy to a degree of statistical significance.

5-HT<sub>3</sub> antagonists include the various setrons such as, for example, palonosetron, ondansetron, dolasetron, tropisetron, and granisetron, and their pharmaceutically acceptable salts. A preferred 5-HT<sub>3</sub> antagonist is palonosetron, especially its hydrochloride salt. Palonosetron is known chemically as (3aS)-2-[(S)-1-Azabicyclo [2.2.2]oct-3-yl]- 2,3,3a,4,5,6-hexahydro-1-oxo-1Hberiz[de] isoquinoline, and is depicted by the following chemical structure of the hydrochloride salt:



Methods of synthesizing palonosetron are described in U.S. Patent Nos. 5,202,333 and 5,510,486. Pharmaceutically acceptable dosage forms are described in PCT publications WO 2004/067005 and WO 2008/049552 from Helsinn Healthcare.

“Highly emetogenic chemotherapy” refers to chemotherapy having a high degree of emetogenic potential, and includes chemotherapy based on carmustine, cisplatin, cyclophosphamide  $\geq 1500$  mg/m<sup>2</sup>, dacarbazine, dactinomycin, mechlorethamine, and streptozotocin.

“Moderately emetogenic chemotherapy” refers to chemotherapy having a moderate degree of emetogenic potential, and includes chemotherapy based on carboplatin, cyclophosphamide  $< 1500$  mg/m<sup>2</sup>, cytarabine  $> 1$  mg/m<sup>2</sup>, daunorubicin, doxorubicin, epirubicin, idarubicin, ifosfamide, irinotecan, and oxaliplatin.

Acute emesis refers to the first twenty-four hour period following an emesis-inducing event. Delayed emesis refers to the second, third, fourth and fifth twenty-four hour periods

following an emesis-inducing event. When a treatment is said to be effective during the delayed phase, it will be understood to mean that the effectiveness of the treatment is statistically significant during the entire delayed phase, regardless of whether the treatment is effective during any particular twenty-four hour period of the delayed phase. It will also be understood that the method can be defined based upon its effectiveness during any one of the twenty-four hour periods of the delayed phase. Thus, unless otherwise specified, any of the methods of treating nausea and/or vomiting during the delayed phases, as described herein, could also be practiced to treat nausea and/or vomiting during the second, third, fourth or fifth twenty-four hour periods following an emesis inducing event, or an combination thereof.

#### Methods of Treatment

As noted above, the invention is premised on several unique discoveries, and provides the following independent methods that can be practiced according to the present invention, including:

In a first principal embodiment, the invention provides a method of treating nausea and vomiting for a period of five consecutive days in a patient in need thereof, comprising administering to said patient netupitant or a pharmaceutically acceptable salt thereof in an amount which is therapeutically effective to treat nausea and vomiting during the acute and delayed phases, which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration.

In a second principal embodiment, the invention provides a combination therapy for treating nausea and vomiting for five consecutive days in a patient in need thereof, consisting essentially of:

(i) administering to said patient on day one netupitant or a pharmaceutically acceptable salt thereof, in an amount which is therapeutically effective to treat nausea and vomiting during the acute and delayed phases, which enters the systemic circulation, crosses the blood brain barrier and occupies at least 70% of NK<sub>1</sub> receptors in the striatum seventy-two hours after said administration;

(ii) administering to said patient on day one a therapeutically effective amount of a 5-HT<sub>3</sub> antagonist (preferably palonosetron, more preferably 0.5 mg. of oral palonosetron as palonosetron hydrochloride) effective to treat said nausea and vomiting during the acute and delayed phases;

(iii) administering to said patient on day one a first dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant and palonosetron, wherein said first dose comprises from 50 to 70% of a minimum effective dose when administered alone; and

(iv) if the patient is undergoing highly emetogenic chemotherapy, administering to said patient, on days two, three and four, a second dose of dexamethasone which is ineffective against nausea and vomiting when administered alone, but effective against nausea and vomiting when administered in combination with said netupitant, wherein said second dose comprises from 40 to 60% of a minimum effective dose when administered alone on days two, three and four.

Various sub-embodiments are envisaged for these principal embodiments. For example, the netupitant can be administered as a free base or a pharmaceutically acceptable salt thereof, but is preferably administered as the free base. In addition, the netupitant is preferably administered in an amount ranging from about 50 to about 500 mg., from about 200 to about 400 mg., and preferably about 300 mg., based on the weight of the free base. A preferred route of administration for the netupitant is oral. In terms of binding to NK<sub>1</sub> receptors, the netupitant preferably binds to at least 80 or even 85% of NK<sub>1</sub> receptors in the striatum seventy-two hours after administration. As of ninety six hours after administration, the netupitant preferably binds less than 70, 60, 50 or even 40% of said NK<sub>1</sub> receptors.

The methods of the present invention are all effective at treating or preventing nausea and vomiting induced by numerous events, including chemotherapy induced nausea and vomiting (“CINV”), from moderately or highly emetogenic chemotherapy, radiation therapy induced nausea and vomiting (“RINV”), and post-operative nausea and vomiting (“PONV”). The method is preferably performed shortly before the emesis inducing event (i.e. no more than 1 or 2 hours before the event). The methods may be used to treat nausea and vomiting during the acute phase of emesis, or during the delayed phase.

The drugs specified by the individual embodiments may be administered by any suitable dosing regimen, as is well known in the art, but in a preferred embodiment the netupitant, 5-HT<sub>3</sub> antagonist and steroid are administered orally. A preferred oral dose of palonosetron ranges from about 0.075 to about 1.0 mg., or from about 0.25 to about 0.75 mg., but is preferably about 0.5 mg. A preferred oral dose of netupitant ranges from about 50 to 500 mg., or from about 200 to about 400 mg., but is preferably about 300 mg. A preferred dose of corticosteroid, preferably

dexamethasone, is 12 mg. administered orally or via injection on the first day of treatment, and 8 mg. administered orally or via injection on the second, third and fourth days after said treatment.

#### Pharmaceutical Compositions

Various pharmaceutical compositions can be developed that make use of the combinations described herein. The composition can be administered by any appropriate route, for example, orally, parenterally, or intravenously, in liquid or solid form.

Preferred modes of administrations of the active compounds are injectable and oral. These compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules (for oral use) or compressed into tablets (for oral or buccal use) or formulated into troches (for buccal use). For these purposes, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.

Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a gliding such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it can contain, in addition to material of the above type, a liquid carrier such as a fatty oil. In addition, dosage unit forms can contain various other materials which modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or other enteric agents.

The compounds can be administered as a component of an elixir, suspension, syrup, wafer, orally disintegrating film, orally disintegrating tablet, chewing gum or the like. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors.

Solutions or suspensions used for injection can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates

and agents for the adjustment of tonicity such as sodium chloride, mannitol and dextrose. An injectable preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

### Combined Oral Dosage Forms

In a preferred embodiment, the invention provides a capsule for oral administration made from a hard outer capsule shell that houses one or more netupitant tablets and one or more palonosetron soft-gel capsules. The finished capsule and the tablet(s) and soft-gel capsule(s) housed within the capsule shell are all preferably formulated as immediate release dosage forms. The number of netupitant units contained within the combined dosage form can be, for example, from 1 to 10, 1 to 5, or 1 to 3. The netupitant units within the combined dosage form can provide anywhere from 50 to 500 mg. of netupitant on an aggregate basis, preferably from 100 to 350 mg. Each netupitant unit preferably comprises from 50 to 200 mg. of netupitant, more preferably 100 to 150 mg. of netupitant, and most preferably 100 or 150 mg. of netupitant.

The palonosetron can also be formulated in any solid form that is suitable for oral administration, although it is preferably formulated as a soft-gel capsule. Non-limiting examples of suitable palonosetron soft-gel capsules are provided in PCT publication WO 2008/049552, the contents of which are hereby incorporated by reference. The number of palonosetron units within the combined dosage form can be, for example, from 1 to 5, from 1 to 3 or just 1. Each of the palonosetron units within the combined dosage form can provide anywhere from 0.01 to 5.0 mg. palonosetron, preferably from 0.1 to 1.0 mg. palonosetron on an aggregate basis. Each palonosetron unit will preferably comprise from 0.1 to 1.0 mg. of palonosetron, most preferably about 0.25, 0.5, 0.75 or 1.0 mg. of palonosetron.

Figure 1 illustrates an exemplary embodiment of a combined oral dosage form of palonosetron and netupitant. The dosage form 10 comprises a two piece hard outer shell that includes a body 20 and a cap 22. The dosage form 10 contains one palonosetron soft-gel capsule 30 (preferably containing 0.5 mg. of palonosetron) and three netupitant tablets 40 (each preferably containing 100 mg. of netupitant).

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds claimed herein are made and evaluated, and are intended to be purely exemplary of the invention and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at room temperature, and pressure is at or near atmospheric.

EXAMPLE 1 – PREPARATION OF ORAL DOSAGE FORM

In a preferred embodiment the combination is administered in a capsule oral dosage form, wherein the capsule houses one or more soft-gel capsules for the palonosetron and one or more hard tablets for the netupitant. Table 1 below describes a representative formulation for a soft-gel capsule containing 0.5 mg. of palonosetron, suitable for inclusion in such a hard outer shell.

TABLE 1: REPRESENTATIVE SOFT-GEL FORMULATION

Ingredient	Approximate Amount (mg/Capsule)	Function
<i>Fill Solution</i>		
Palonosetron HCl	0.56 <sup>1</sup>	Active
Mono- and di-glycerides of Capryl/Capric Acid (Capmul MCM)	62.19	Solvent vehicle
Glycerin, anhydrous, USP/Ph Eur	3.37	Plasticizer
Polyglyceryl oleate (Plurol Oleique CC 497)	0.87	Surfactant
Purified water, USP/Ph Eur	2.94	Co-solvent
Butylated hydroxyanisole (BHA), NF/Ph Eur	0.07	Antioxidant
Nitrogen	-	
Theoretical fill weight	70.00 mg	
<i>Gelatine Capsule Shell, 1.5-oval (Catalent Pharma Solutions)<sup>2</sup></i>		
Gelatine (type 195), NF/Ph Eur	-	Shell
Sorbitol Special/Glycerin Blend 50/50	-	Plasticizer
Titanium dioxide, USP/Ph Eur	-	Colorant/Opacifier
Purified water, USP/Ph Eur	-	Solvent

<sup>1</sup>Corresponds to 0.50 mg. free base<sup>2</sup>Quantitative composition of capsule shell is proprietary to Catalent Pharma Solutions

Table 2 below describes a representative formulation for a tablet containing 100 mg. of netupitant, suitable for inclusion in a hard shell.

TABLE 2: REPRESENTATIVE TABLET FORMULATION

Ingredient	Approximate Amount (mg/Tablet)	Function
Netupitant, milled	100	Active
Microcrystalline cellulose pH 101	20.5	Diluent and disintegrant
Sucrose Lauric Acid Esters	10.0	Surfactant
Polyvinylpyrrolidone K30	7.0	Binder
Sodium croscarmellose	3.0	Disintegrant
Colloidal Silicon Dioxide	3.0	Glidant
Sodium Stearyl Fumarate	1.0	Lubricant
Magnesium Stearate	0.5	Lubricant
Total weight	145 mg	

#### EXAMPLE 2 – PHARMACOKINETICS OF COMBINED DOSAGE FORM

##### Objective

The effects of palonosetron on the pharmacokinetics (PK) of netupitant and the effects of netupitant on the PK of palonosetron were examined in healthy volunteers.

##### Methods

A randomized, open, 3-way crossover study was conducted. Each subject participated in 3 treatment periods, each lasting approximately 12 days (Day -1 to Day 11). The treatment periods were separated by wash-out periods of no less than 14 days (between Day 1 of any 2 consecutive treatment periods).

The following treatments were investigated:

Treatment A: oral netupitant 450 mg. administered as single dose of three 150 mg. capsules.

Treatment B: oral palonosetron 0.75 mg. and oral netupitant 450 mg. administered simultaneously as three capsules of 150 mg. netupitant followed by 1 capsule of 0.75 mg. palonosetron.

Treatment C: oral palonosetron 0.75 mg. administered as single dose as one 0.75 mg. capsule.

Doses were administered under fasting conditions. Subjects fasted over-night for approximately 10 hours. Water, however, was permitted up to 1 hour pre-dose. Food intake was permitted 4 hours post-dose, and water was allowed ad libitum 1 hour post-dose.

Doses were administered with the subject in an upright position. The subjects remained in an upright position for 4 hours post-dose. The capsules were swallowed whole with 250 mL of room-temperature tap water. Repeated PK blood sampling (for netupitant and/or palonosetron) was performed.

### Results

The primary PK variables assessed for netupitant and palonosetron were the maximum plasma concentration observed ( $C_{max}$ ), the area under the plasma concentration versus time curve from time zero to the last quantifiable sampling time point (t) ( $AUC_{0-t}$ ), and the area under the plasma concentration versus time curve from time zero to infinity ( $AUC_{0-inf}$ ). The secondary PK variables assessed were the terminal elimination half-life ( $t_{1/2,z}$ ), and the time at which the maximum plasma concentration was observed ( $t_{max}$ ). Results are depicted in Figures 2 and 3.

### EXAMPLE 3: NETUPITANT + DEXAMETHASONE DRUG INTERACTION STUDY

The effect of netupitant on orally administered dexamethasone pharmacokinetics was evaluated in this study. This was a randomized, open, 3-period crossover study utilizing an incomplete Latin Square design where subjects were given dexamethasone alone, or oral Netupitant 100 mg., 300 mg. or 450 mg. each given with dexamethasone. Netupitant was given orally on Day 1 only. The dexamethasone regimen for each treatment was 20 mg. orally Day 1, followed by 8 mg. orally every 12 hours from Day 2 through Day 4. Nineteen subjects (12 male and 7 female) completed the study (i.e., all 3 treatment periods).

Mean plasma concentrations of dexamethasone were higher when dexamethasone was co-administered with netupitant (Figure 4). The increase appeared to be dependant on the netupitant exposure.

The  $AUC_{0-24}$  (Day 1) of dexamethasone increased 1.5, 1.7 and 1.8-fold with co-administration of 100, 300 and 450 mg. netupitant, respectively. The  $AUC_{24-36}$  (Day 2) of

dexamethasone increased 2.1, 2.4 and 2.6-fold and  $AUC_{84-108}$  and  $AUC_{84-inf}$  (Day 4) increased 1.7, 2.4 and 2.7-fold, with co-administration of 100, 300 and 450 mg. netupitant, respectively. Dexamethasone  $C_{max}$  on Day 1 was only slightly affected by co-administration of netupitant (1.1-fold increase during co-administration with 100 and 300 mg. netupitant, respectively, and 1.2-fold increase during co-administration with 450 mg. netupitant).  $C_{max}$  on Day 2 and Day 4 was increased approximately 1.7-fold in subjects administered netupitant. Dexamethasone  $C_{min}$  on Days 2-4 was increased approximately 2.8, 4.3 and 4.6-fold with co-administration of 100, 300 and 450 mg. netupitant, respectively.

#### EXAMPLE 4: NETUPITANT PET RECEPTOR OCCUPANCY STUDY

This was a randomized, open-label, positron emission tomography (PET) study using  $^{11}C$ -GR205171 as tracer in 6 healthy male volunteers (2 per dose level) receiving single doses of netupitant (100, 300 or 450 mg) to investigate the degree of occupancy of  $NK_1$  receptors in human brain, and to determine the relationship between plasma concentration of netupitant and  $NK_1$  receptor occupancy (RO).

The anticipated high  $NK_1$ -RO (90% or higher) close to the expected  $C_{max}$  (6 hours post dose) was reached for striatum, occipital cortex, frontal cortex and anterior cingulate in 3 of 6 subjects of whom 1 received 300 mg. and 2 received 450 mg. of netupitant as a single oral dose.

All doses showed a relatively long duration of blockade of  $NK_1$  receptors and the decline over time was dose dependent. In the 100 mg. dose group, 4 of 6 regions still had a mean  $NK_1$ -RO over 70% at 96 hours post dose. In the highest dose group (450 mg), 5 of 6 regions had a mean  $NK_1$ -RO of 80% or higher at 96 hours post dose. A comparison of the results for the dose groups (100 mg., 300 mg. and 450 mg) showed a consistent but small increase in  $NK_1$ -ROs with increasing netupitant dose. (Figure 5)

#### EXAMPLE 5: CLINICAL EFFICACY STUDY

A phase 2 trial evaluated three single doses of netupitant combined with palonosetron and dexamethasone compared to palonosetron alone and dexamethasone to obtain dose ranging information for netupitant used with oral palonosetron in the CINV patient population.

The objective of the study was to compare the efficacy and safety of three single oral doses of netupitant combined with oral palonosetron and given with dexamethasone, versus oral

palonosetron-alone given with dexamethasone (without netupitant) for the prevention of highly emetogenic chemotherapy (HEC)-induced nausea and vomiting. The FDA-approved oral aprepitant regimen given with IV ondansetron and dexamethasone was included in the study as an active comparator for exploratory purposes. The FDA-approved oral palonosetron 0.5 mg. dose was used in each applicable treatment group in this study.

This was a multicenter, randomized, double-blind, double-dummy, parallel group, stratified study. Eligible patients were randomized (stratified by gender) to one of the following treatment groups:

Group 1 – 0.5 mg. oral palonosetron on Day 1 (with an oral dexamethasone standard regimen: 20 mg. on Day 1 and 8 mg. BID from Day 2 through Day 4)

Group 2 – 100 mg. oral netupitant plus 0.5 mg. oral palonosetron on Day 1 (with an oral dexamethasone adjusted regimen\*: 12 mg. on Day 1 and 8 mg. daily from Day 2 through Day 4)

Group 3 – 200 mg. oral netupitant plus 0.5 mg. oral palonosetron on Day 1 (with an oral dexamethasone adjusted regimen\*: 12 mg. on Day 1 and 8 mg. daily from Day 2 to Day 4)

Group 4 – 300 mg. oral netupitant plus 0.5 mg. oral palonosetron on Day 1 (with dexamethasone adjusted regimen\*: 12 mg. on Day 1 and 8 mg. daily from Day 2 to Day 4)

Group 5 – 125 mg. oral aprepitant plus IV ondansetron 32 mg. (both on Day 1) then 80 mg. oral aprepitant on Day 2 and Day 3, (all with an oral dexamethasone adjusted regimen: 12 mg. on Day 1 and 8 mg. daily from Day 2 through Day 4)

The primary efficacy endpoint was the complete response rate (defined as no emetic episodes, no rescue medication) within 120 hours after the start of the highly emetogenic chemotherapy administration. Secondary efficacy endpoints were:

- Complete response for the 0-24 hour interval (acute phase); and for the 25-120 hour interval (delayed phase);
- Complete protection (defined as no emesis, no rescue therapy, no significant nausea); Total control (defined as no emesis, no rescue therapy and no nausea); No nausea (maximum VAS <5 mm); No significant nausea (maximum VAS <25 mm); No rescue medication; No emesis. These endpoints were evaluated for the 0-120 hour interval (overall), acute and delayed phase.

- Time to first emetic episode, Time to first rescue medication, Time to treatment failure (based on time to the first emetic episode or time to the first rescue medication, whichever occurs first);
- Severity of nausea for the overall, acute and delayed phase; • Patient global satisfaction with anti-emetic therapy by means of VAS for each 24hour interval.

Complete response rates are summarized in Table 3. The percent of patients with complete response over 0-120 hours after start of cisplatin administration was 76.5% in the palonosetron alone group and 87.4%, 87.6%, and 89.6% in the netupitant 100 mg., 200 mg., and 300 mg. groups, respectively. Differences from palonosetron-alone were greater than 10% (10.9% to 13.2%). All doses of netupitant were statistically superior to palonosetron alone (p-value=0.004 for the netupitant 300 mg. combination group).

**TABLE 3: COMPLETE RESPONSE RATE FOR THE OVERALL, ACUTE AND DELAYED PHASE: MFAS Population**

Efficacy endpoint	Palo alone (n=136)	Palo + Netu 100 mg (n=135)	Palo + Netu 200 mg (n=137)	Palo + Netu 300 mg (n=135)	Aprepitant Regimen (N=134)
<b>CR, Overall Phase, 0-120h</b>					
Percent of Patients	76.5	87.4	87.6	89.6	86.6
Difference from Palo alone (%)		10.9	11.1	13.2	10.1
p-value (*)		0.018	0.017	0.004	0.027
<b>CR, Acute Phase, 0-120h</b>					
Percent of Patients	89.7	93.3	92.7	98.5	94.8
Difference from Palo alone (%)		3.6	3.0	8.8	5.1
p-value (*)		0.278	0.383	0.007	0.114
<b>CR, Delayed Phase, 25-120h</b>					
Percent of Patients	80.1	90.4	91.2	90.4	88.8
Difference from Palo alone (%)		10.2	11.1	10.2	8.7
p-value (*)		0.018	0.010	0.018	0.043

(\*) p-value from logistic regression analysis, aprepitant p-value from post-hoc logistic regression analysis.

Table 4 summarizes results for main secondary endpoints. In the overall phase, 76.5% of patients in the palonosetron-alone group did not experience emesis, while 87.4, 87.6, and 91.1% of patients did not experience emesis in the netupitant 100 mg., 200 mg. and 300 mg. combination groups, respectively (p<0.05 for all doses).

**TABLE 4: SUMMARY OF SECONDARY EFFICACY RESULTS: PERCENT OF PATIENTS, MFAS POPULATION**

Efficacy endpoint	Palo alone (n=136)	Palo + Netu 100 mg (n=135)	Palo + Netu 200 mg (n=137)	Palo + Netu 300 mg (n=135)	Aprepitant Regimen (N=134)
<b>No Emesis</b>					
Overall	76.5	87.4*	87.6*	91.1*	87.3*
Acute	89.7	93.3	92.7	98.5*	94.8
Delayed	80.1	90.4*	91.2*	91.9*	89.6*
<b>No Rescue</b>					
Overall	95.6	97.8	100	98.5	97.8
Acute	97.8	99.3	100	100	100
Delayed	97.1	97.8	100	98.5	97.8
<b>No Nausea</b>					
Overall	50.7	54.8	62.0	61.5	58.2
Acute	75.0	72.6	77.4	80.0	77.6
Delayed	53.7	59.3	65.0	68.1*	60.4
<b>No Significant Nausea</b>					
Overall	79.4	80.0	86.1	89.6*	85.8
Acute	93.4	94.1	94.2	98.5*	94.0
Delayed	80.9	81.5	89.8*	90.4*	88.1
<b>Total Control</b>					
Overall	50.0	54.8	61.3	59.3	56.0
Acute	71.3	71.9	76.6	80.0	74.6
Delayed	52.2	59.3	65.0*	65.9*	58.2
<b>Complete Protection</b>					
Overall	69.9	76.3	80.3*	83.0*	78.4
Acute	87.5	89.6	88.3	97.0*	89.6
Delayed	73.5	80.0	87.6*	84.4*	82.1

\* p-value <0.05 compared with palonosetron-alone; aprepitant comparisons p-values calculated by post-hoc analysis

**EXAMPLE 7: COMPARATIVE RESULTS OF APREPITANT DOSING REGIMEN**

The following Table 6 reports the results observed for an aprepitant dosing regimen, as described in the FDA approved prescribing information for aprepitant. Table 5 reports the dosing regimen:

**TABLE 5**

Treatment Regimen	Day 1	Days 2 to 4
Aprepitant	Aprepitant 125 mg PO Dexamethasone 12 mg PO Ondansetron 32 mg IV	Aprepitant 80 mg PO Daily (Days 2 and 3 only) Dexamethasone 8 mg PO Daily (morning)

**TABLE 6**  
**Percent of Patients Receiving Highly Emetogenic Chemotherapy Responding by Treatment Group and Phase for Study 1 — Cycle 1**

ENDPOINTS	Aprepitant Regimen (N = 260) <sup>†</sup> %	Standard Therapy (N = 261) <sup>†</sup> %	p-Value
<b>PRIMARY ENDPOINT</b>			
Complete Response Overall <sup>‡</sup>	73	52	<0.001
<b>OTHER PRESPECIFIED ENDPOINTS</b>			
Complete Response			
Acute phase <sup>§</sup>	89	78	<0.001
Delayed phase <sup>  </sup>	75	58	<0.001
Complete Protection			
Overall	63	49	0.001
Acute phase	85	75	NS*
Delayed phase	66	52	<0.001
No Emesis			
Overall	78	55	<0.001
Acute phase	90	79	0.001
Delayed phase	81	59	<0.001
No Nausea			
Overall	48	44	NS**
Delayed phase	51	48	NS**
No Significant Nausea			
Overall	73	66	NS**
Delayed phase	75	69	NS**

<sup>†</sup>N: Number of patients (older than 18 years of age) who received cisplatin, study drug, and had at least one post-treatment efficacy evaluation.

<sup>‡</sup>Overall: 0 to 120 hours post-cisplatin treatment.

<sup>§</sup>Acute phase: 0 to 24 hours post-cisplatin treatment.

<sup>||</sup>Delayed phase: 25 to 120 hours post-cisplatin treatment.

\*Not statistically significant when adjusted for multiple comparisons.

\*\*\*\*\*

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.